logo

Ardelyx, Inc (ARDX)



Trade ARDX now with
  Date
  Headline
8/6/2020 8:06:49 AM Ardelyx, Inc. Q2 Net Loss $25 Mln Vs. Net Loss $25.5 Mln Last Year
6/30/2020 8:17:11 AM Ardelyx Submits NDA To FDA For Tenapanor For The Control Of Serum Phosphorus In Adult Patients With CKD On Dialysis
6/15/2020 8:06:53 AM Ardelyx Announces Positive Second Data Analysis From NORMALIZE Phase 4 Study Of Tenapanor In CKD Patients On Dialysis
6/8/2020 4:02:58 PM Ardelyx Appoints Justin Renz As CFO
5/18/2020 4:04:43 PM Ardelyx Appoints Susan Rodriguez As Chief Commercial Officer
3/6/2020 4:03:00 PM Ardelyx Q4 Loss/share $0.27 Vs. Loss $0.45 Year Ago
12/4/2019 11:51:19 PM Ardelyx Announces Pricing Of Upsized Public Offering Of 20 Mln Shares At $6.25/Shr
12/3/2019 7:28:42 AM Ardelyx Announces Positive Topline Results From Phase 3 PHREEDOM Study Showing Tenapanor In CKD Patients On Dialysis
10/4/2019 6:15:36 AM New Drugs Approved In September
9/3/2019 8:06:59 AM Ardelyx Announces Positive Results From Pivotal Phase 3 AMPLIFY Study; Stock Surges